摘要
Abstract
Objective To evaluate the clinical effects of ticagrelor tablets in combination with aspirin for the treatment of a-cute myocardial infarction(AMI).Methods From January 2022 to June 2023,70 AMI patients treated at our hospital were enrolled and randomly assigned to a control group(n=35)and a study group(n=35).The control group received aspirin plus clopidogrel,while the study group received aspirin plus ticagrelor.Clinical efficacy,coagulation function indices,myo-cardial enzyme spectrum parameters,and the incidence of adverse events were compared between the two groups.Results The study group demonstrated a significantly higher overall response rate compared with the control group(P<0.05).Post-treatment,the study group exhibited longer prothrombin time(PT)and activated partial thromboplastin time(APTT),and lower fibrinogen(FIB)levels than the control group(all P<0.05).Myocardial injury markers-including lac-tate dehydrogenase(LDH),creatine kinase-MB(CK-MB),and total creatine kinase(CK)-were significantly lower in the study group(P<0.05).Moreover,the incidence of adverse reactions in the study group was significantly lower than in the control group(P<0.05).Conclusion In AMI patients,ticagrelor combined with aspirin enhances therapeutic efficacy,op-timizes coagulation profiles and myocardial enzyme parameters,alleviates clinical symptoms,and reduces the risk of throm-boembolic events.关键词
急性心肌梗死/替格瑞洛片/阿司匹林/凝血功能/血栓栓塞症Key words
Acute myocardial infarction/Ticagrelor/Aspirin/Coagulation function/Thromboembolism分类
医药卫生
